Gastric and Esophageal
- Colon, Esophagus, Liver, PancreasAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid TumorsPrincipal Investigator: Michael Cecchini
- Lung, StomachA Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Principal Investigator: Sarah Goldberg
- Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Thyroid, Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Principal Investigator: Barbara Burtness
- Esophagus, Larynx, Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCAPrincipal Investigator: Aarti Bhatia
- Anus, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites, Breast, Cervix, Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced CancerPrincipal Investigator: Francine Foss